This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the potential of Nektar's Rezpegaldesleukin (IL-2 inhibitor) in patients with Alopecia Areata

Ticker(s): NKTR

Who's the expert?

Institution: Harvard

  • Associate Professor of Dermatology at Harvard Medical School and Vice Chair of Clinical Trials and Innovation at Brigham and Women’s Hospital, specializing in alopecia areata and complex medical dermatology.

  • Currently manages over 150 patients with alopecia areata.

  • Medical Director of the Dermatology Consult Service and Co-Director of the Complex Medical Dermatology Fellowship Program, with over 7,500 citations for research on diagnostic testing and health disparities.

Interview Goal
This call will feature a discussion on the current treatment landscape for alopecia areata along with the potential of Nektar's Rezpegaldesleukin.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.